## SUPPLEMENTARY APPENDIX

# The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family 

Christina Bade-Döding, ${ }^{1,2 *}$ Alex Theodossis, ${ }^{3 *}$ Stephanie Gras, ${ }^{3}$ Lars Kjer-Nielsen, ${ }^{2}$ Britta Eiz-Vesper, ${ }^{1}$ Axel Seltsam, ${ }^{4}$ Trevor Huyton, ${ }^{1}$ Jamie Rossjohn, ${ }^{3}$ James McCluskey, ${ }^{2 \#}$ and Rainer Blasczyk ${ }^{1{ }^{1 *}}$
*joint first authors; "joint senior authors
${ }^{1}$ Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany; ${ }^{2}$ Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; ${ }^{3}$ Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, and ${ }^{4}$ German Red Cross Blood Donor Service NSTOB, Institute Springe, Springe, Germany

Citation: Bade-Döding C, Theodossis A, Gras S, Kjer-Nielsen L, Eiz-Vesper B, Seltsam A, Huyton T, Rossjohn J, McCluskey J, and Blasczyk R. The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family. Haematologica 2011;96(1):110-118. doi:10.3324/haematol.2010.030924

Online Supplementary Table S1. Ligands of the HLA-B*41 variants.

## HLA-B*41:01

|  |  |  | e | - |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |  |
| Ligands |  |  |  |  |  |  |  |  |  |  |
|  | A | A | L | T | G | R | T | G | P | P |
|  | M | K | L | P | V | P | A | A | A | P |
|  | Y | E | E | G | P | G | K | N | L | P |
|  | K | A | $Y$ | G | D | R | I | E | R | M |
|  | A | E | I | Q | G | V | 1 | D | A |  |
|  | G | G | G | Y | T | I | R | N | v |  |
|  | E | K | A | P | A | P | A | P | E |  |
|  | K | S | I | P | A | s | F | G | T |  |
|  | K | E | 1 | S | E | N | E | V | v |  |
|  | P | H | v | P | P | P | V | P | P |  |
|  | K | E | G | K | P | P | I | S | v |  |
|  | Q | D | I | A | N | E | D | A | v |  |
|  | M | E | K | G | G | N | M | K | E |  |
|  | T | E | E | K | F | I | V | K | A |  |
|  | H | R | E | V | c | H | P | E | v |  |
|  | G | R | P | P | E | M | P | v |  |  |

## Source

NuC3B mucin
Tuftelin interacting protein 11
Cytochrome $C$ oxidase VIIc
Heat shock protein gp96 precursor
FOS-like antigen 2
Transmembrane-type protein tyrosine phosphatase H
KIAA1168 protein
FLJ00259 protein
dJ756N5.1.1(Continues in Em:AL133324 as dJ1161H23.3)
Sal-1ike 3; C2H2 zinc finger protein SALL3
Unnamed protein product (hum.)
Hypothetical protein XP_209384
Karyopherin $\alpha$ 1; importin $\alpha$ 5; importin- $\alpha-$ S1 SCAP protein
Nucleolar protein GU2; RNA helicase II/Gu $\beta$
MLL2 protein

HLA-B*41:02

## Peptide position

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## Ligands

| G | E | K | F | E | D | E | N | F |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | E | v | D | G | K | Q | V | E | L |
| A | E | K | L | G | G | 5 | A | V | I |
| A | E | E | K | A | A | $v$ | T | S | L |
| $Y$ | E | E | G | P | G | K | N | L | P |
| K | E | E | P | P | Q | P | Q | 1 |  |
| K | E | G | K | P | P | I | S | V |  |
| Q | E | E | H | V | A | V | A | $Q$ |  |
| P | A | V | P | P | P | P | V | P |  |
| $\pm$ | P | H | P | G | P | $F$ | G | S |  |
| G | E | V | D | P | K | V | A | L |  |
| 1 | E | K | Q | P | P | 0 | v | L |  |
| K | E | T | E | I | V | Q | L | Q |  |
| A | E | A | 1 | E | R | M | $F$ | L |  |
| R | E | D | K | K | Q | V | Q | F |  |
| A | E | A | E | R | V | G | L |  |  |
| K | E | R | S | G | v | S | L |  |  |
| W | A | L | 1 | T | L | V | L |  |  |
| S | E | $F$ | P | I | R | T | L |  |  |
| E | E | P | F | M | P | E | E |  |  |
| F | E | K | T | $Q$ | E | E | I |  |  |

[^0]
## Peptide position

$\begin{array}{llllllllllllllll}1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 & 9 & 10 & 11 & 12 & 13 & 14 & 15 & 16\end{array}$
Ligands

```
A E M Y G S V T E H P S P S P L
H E R E P E E I V K M E E
F E K T Q E E L T P E F
F E P L N K P D S T I Q
G E K F E D E N F I IL
F I V N C T V N V Q D
I E V D G K Q V E L
G E E H F K G L V L
E K L F E E K E K P
R E L E E T N O K L
A Y G D R I E R M
K E D D V R Q Y V V
E N D E D R L V L
K E M M A M M L Q K K K I
I N E D R L P H L I
E D E D S L K T T I
E Y I Q K N V O I
D I N O D N L Q L
E K S Q L V R P I
|
E D Y D E R V L P
K
L Q S L T L F L O
E E G P P K E E M T L
E D D G Q P R T I
V E D D R T L Q S L
V E E I S R T Q P I
V E I E E R G V K I
f E D I K K G I L I
L L W S V V T V V S I I F
S E V N P N T R V M
k E E P S N N V K L
E I E S T K G E I
E K N G D V V E L
E V D V E Q H T I
E Y P P I V D D G K I
S R V O D A S K I
E A P V Q E E K L
E N G F L P I H.L
A E P K P K P O L
A E A V M L G Q P
S E G A L A I E V
E Q Q G K G V A L
S A A V G S V V L
T G A S G S F K I
E A P P T N Q A
E D P A G L K V
N S P S G N N I
E G K P T P A L
E A P P G T P P
E V D P K V A L
E I I G V K V I
E V V V K E E G L
G L Q E P V G R
E D G K V V T V
E A S M I S K L
E E G Y G R S L
D S D A T S P R
E N E A E T K L
E D I P V K T L
E D L A R I S L
E G K D L P E H
E E L G H R D V
D K I P P L L L V V
E I N N I I K I
P Q N A D K I K
E E N T G H T F
E E L O M E P V
T V K V K E S F
E V N F T S E L
L L K G H K K L
E
G Y D S I I Y R
```


## Source

Heterogeneous nuclear ribonucleoprotein C1/C2
KIAA0820 protein
Apolipoprotein A-II
Ubiquitin-specific protease 15
Peptidylprolyl isomerase A
Unnamed protein product (hum.)
Rho-related GTP-binding protein RhoB (H6)
Bovine albumin
OG-2 homeodomain protein-1ike
CDR2_HUMAN Cerebellar degeneration-related protein 2.
Heat shock protein gp96 precursor
Unnamed protein product (hum.)
Unnamed protein product (hum.)
GRIP coiled-coil protein GCC185 isoform a
Signal transducing adaptor molecule 2 B
DNA topoisomerase II, alpha isozyme
KIAA1901 protein
Cardiac ankyrin repeat protein;
Cyclin B3
Nucleolar protein family A, member 3
Cytochrome P450 4F2
Similar to KIAA1509 protein
Mitochondrial intermediate peptidase
Adenvlate cvelase 6 isoform a
TIA1 cytotoxic granule-associated RNA-binding protein
Like 1 isoform 1
ELAVL4 protein
Tumor necrosis factor receptor superfamily
Septin-2 (Protein NEDD5)
MCM4_HUMAN DNA replication licensing factor MCM4
ALKB_HUMAN alkylated DNA repair protein al kB homolog
Hypothetical protein FLJJ20323
Hypothetical protein KIAA0612
Unnamed protein product (hum.)
Hypothetical protein (hum, herpesvirus 7)
Cyclin B1
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2
Unnamed protein product (hum.)
Jumping translocation breakpoint; PAR protein
Claudin-18A2.1
HS1-binding protein 3, iso. 1
Calcineurin-binding protein calsarcin-2
bA93B14.1.1 solute carrier fam. 21 org. anion transp.
IF4G_HUM, euk. transl. initiation factor $4 \gamma$ (eIF-4- $\gamma$ )
Filamin C, gamma (actin-binding protein-280)
Hl histone family, member 5
FLJJ00163 protein
Major capsid protein (hum. herpesvirus 4)
dJ309k20.1.1 (nov. proteln sim. to dysferlin, iso. 1)
IMMT_HUM. mitoch. membr. protein (Mitofilin) (p87/89)
R28379_3
A34653 cell adhesion proteln SQM1
Similar to KIAA0606 protein
Tolloid-1ike 2
AATK protein
JC2186 hippocalcin
Hypothetical protein KIAA0052
Anaphase-promoting complex subunit 5
Axonal transp. synaptic vesicles; kinesin, hc, IA
Glutamyl-prolyl tRNA synthetase; glutamate tRNA lig.
Isoleucyl-tRNA synthetase, cytoplasmic
Unnamed protein product (hum.)
S22765 heterogeneous ribonuclear particle protein $U$ Hypothetical protein FLJ40243
Similar to melanoma chondroitin sulfate proteoglycan
KIAA0853 protein
Muscle-specific serine kinase I
ASC-1 complex subunit P200
Hypothetical protein XP_291339
Probable ribosome biogenesis protein
Targeting protein for Xklp2
Hypothetical protein (hum.)
Dyskerin
HT028

| K | E | T | E | I | V | Q | $L$ | Q |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E | T | V | N | R | I | M | T | L |
| A | E | A | L | E | R | M | F | L |
| K | E | I | D | K | N | D | H | 1 |
| A | E | K | E | F | N | E | T | M |
| K | E | K | P | D | I | F | Q | L |
| E | E | 0 | 0 | K | 0 | Q | L | Q |
| H | E | Q | E | E | I | F | K | L |
| E | K | L | E | R | K | E | I | Q |
| F | E | D | E | E | 1 | K | R | L |
| $Y$ | E | E | 1 | F | V | K | N | M |
| R | E | E | Y | P | D | R | 1 | M |

## HLA-B*41:04

## Peptide position

$\begin{array}{lllllllllllllll}1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 & 9 & 10 & 11 & 12 & 13 & 14 & 15\end{array}$
Ligands

| A | E | $Y$ | G | R | L | G | L | G | E | G | A | E | E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A | E | N | P | G | K | Y | N | I | L | G | T | N | T |
| A | E | V | E | G | K | D | L | P | E | H | A | v | L |
| G | E | Y | 1 | P | S | K | G | A | G | N | N | v | L |
| $K$ | E | E | P | P | Q | P | Q | L | A | N | G | A | L |
| A. | E | $Q$ | A | E | R | Y | D | D | M | A | S | A | M |
| A | E | A | G | A | G | S | A | T | E | F | Q | F |  |
| M | E | E | D | P | $Q$ | T | S | R | E | 1 | F | N |  |
| 1 | E | I | N | P | D | H | P | I | V | E | T | L |  |
| S | E | M | E | v | $Q$ | D | A | E | 1 | K | A | 1 |  |
| Y | E | D | F | K | E | E | G | S | E | N | A | V |  |
| D | E | V | G | G | E | A | L | G | R | L | L |  |  |
| A | E | v | G | D | G | T | T | S | V | T | 1 |  |  |
| T | E | I | D | E | K | E | Y | I | S | L |  |  |  |
| $Y$ | E | E | N | E | E | F | 1 | R | T | M |  |  |  |
| G | E | K | F | E | D | E | N | F | 1 | L |  |  |  |
| 1 | E | v | D | P | D | T | K | E | M | L |  |  |  |
| K | E | F | D | G | K | S | 1 | $v$ | S | $v$ |  |  |  |
| R | E | E | L | S | N | V | 1 | A | A | M |  |  |  |
| K | E | L | S | E | D | E | 1 | R | T | L |  |  |  |
| H | E | E | A | V | S | V | D | R | V | L |  |  |  |
| E | D | A | 1 | P | P | I | V | L | R | S |  |  |  |
| S | I. | I | D | R | S | S | A | P | E | L |  |  |  |
| A | E | E | K | A | A | V | T | S | L |  |  |  |  |
| $Y$ | E | D | $Y$ | $Y$ | $Y$ | H | P | P | P |  |  |  |  |
| I | E | v | D | G | K | Q | v | E | L |  |  |  |  |
| A | E | E | L | P | H | I | H | A | F |  |  |  |  |
| A | E | K | v | E | 1 | A | T | L |  |  |  |  |  |
| S | E | E | D | F | I | R | S | L |  |  |  |  |  |
| $Y$ | G | A | E | A | 1 | E | R | M |  |  |  |  |  |
| $Y$ | E | E | I | E | V | K | N | M |  |  |  |  |  |
| V | E | K | I | D | F | D | S | v |  |  |  |  |  |
| A | E | E | D | F | $Y$ | E | K | L |  |  |  |  |  |
| T | E | D | I | P | V | K | T | L |  |  |  |  |  |
| M | L | L | A | F | Y | E | K | I |  |  |  |  |  |
| F | E | E | I | Y | P | P | E | v |  |  |  |  |  |
| D | T | E | $v$ | K | T | L | K | L |  |  |  |  |  |
| R | E | E | P | D | L | V | 1 | L |  |  |  |  |  |
| N | E | D | w | E | N | P | Q | L |  |  |  |  |  |
| A | E | L | 1 | V | Q | P | E | L |  |  |  |  |  |
| K | E | L | G | I | T | A | L |  |  |  |  |  |  |
| F | E | D | E | s | F | A | v |  |  |  |  |  |  |
| G | E | A | L | G | R | L | L |  |  |  |  |  |  |
| H | w | P | F | G | A | L | L |  |  |  |  |  |  |
| $Y$ | S | D | M | K | R | A | L |  |  |  |  |  |  |
| D | M | E | N | E | F | 1 | L |  |  |  |  |  |  |
| I | R | 1 | L | E | E | A | L |  |  |  |  |  |  |
| G | E | I | E | A | 1 | E | L |  |  |  |  |  |  |
| G | E | D | V | v | T | L | L |  |  |  |  |  |  |
| F | E | D | E | N | $F$ | I | L |  |  |  |  |  |  |
|  | E |  |  |  |  |  |  |  |  |  |  |  |  |

Hypothetical protein SP329
Laminin $\beta 1$ related protein
Hemoglobin $\alpha 1$ globin chain
Hypothetical protein ELJ32343
Jumonji domain containing 2
SACS_HUMAN sacsin
Hypothetical protein LOC139135
Similar to tousled-1ike kinase 2
Protein kinase C $\boldsymbol{\beta}$ ( 5 ' partial) splice form 1 Osteoblast specific factor 2 (fasciclin I-like)
Tissue factor pathway inhibitor
Unnamed protein product (hum.)

## Source

Unnamed protein product (hum.)
Regulator of chromosome condensation
Heterogenous nuclear ribonucleoprotein
Heterogeneous ribonuclear particle protein $U$ Unnamed protein product (hum.)
Protein C20orf24
14-3-3 protein eta (Protein AS1)
40 S ribosomal protein S 10
Unnamed protein product (hum.)
Heat shock protein HSP 90- $\boldsymbol{\beta}$ (HSP 90) Proliferation-associated protein 2G4 Putative GTP-binding protein PTD004 Hemoglobin beta subunit
T-complex protein 1
Proteasome activator complex subunit 3
UPF0315 protein AD-001
Peptidyl-prolyl cis-trans isomerase A
40 S ribosomal protein $\$ 17$
Heat shock protein HSP 90- $\beta$
60 ribosomal protein L36
52 kD repressor of protein kinase inhibitor
S-methyl-5-thioadenosine phosphorylase
Serine/threonine protein kinase 19
Cytoplasmic linker protein 2
caspr5 protein isoform 1
Heterogeneous nuclear ribonucleoprotein R
Rho-related GTP-binding protein RhoB (H6) BolA-1ike protein 2
Proteasome subunit $\alpha$ type 4
FYVE finger-contain. phosphoinositide kinase
Hemoglobin a subunit
Tissue factor pathway inhib. (TFPI)
Eukaryotic transl. initiation factor 3 subunit 12
DNA replication licensing factor MCM7
Isoleucyl-tRNA synthetase, cytoplasmic
Fucose-1-phosphate guanylyltransferase
Cyclin-A2
Zinc finger protein HRX (ALL-1)
Menin
G2/mitotic-specific cyclin-B2
Desmoplakin
40 S ribosomal protein 514
Peptidyl-prolyl cis-trans isomerase G
Hemoglobin beta subunit
Somatostatin receptor type 1 (SS1R)
Splicing factor, arginine/serine-rich 6
Zinc finger protein 198
DNA-dependent protein kinase catalytic subunit
Heterogeneous nuclear ribonucleoprotein A/B
Hexokinase-2
Peptidyl-prolyl cis-trans isomerase A
Septin-2 (protein NEDD5)

## Peptide position

$\begin{array}{lllllllllllll}1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 & 9 & 10 & 11 & 12 & 13\end{array}$

## Ligands

| P | E | P | L | P | S | W | V | A | R | L | D | 1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| F | G | S | G | A | G | A | s | c | V | N | L | 1 |
| V | E | $Y$ | R | G | Q | A | $Q$ | A | 1 | E | E | L |
| 1 | E | I | N | P | D | H | P | I | V | E | T | L |
| Y | E | P | N | M | S | V | G | F | T | A | v |  |
| A | E | V | K | K | P | G | A | S | M | K | v |  |
| A | E | V | K | R | P | G | E | S | 1 | R | 1 |  |
| 1 | S | L | S | S | P | 0 | V | P | G | S | P |  |
| N | G | D | v | G | A | V | S | E | P | P |  |  |
| V | c | G | K | P | F | H | S | 1 | S | P |  |  |
| A | E | V | T | $v$ | S | A | S | G | 1 | 1 |  |  |
| D | E | A | T | 1 | R | A | I | I | A | v |  |  |
| K | E | 1 | E | 4 | M | p | E | K | G | L |  |  |
| $Y$ | S | S | T | W | S | G | G | Y | G | L |  |  |
| 1 | L | P | G | G | G | L | L | P | T | P |  |  |
| S | E | E | A | R | K | 1 | M | $\checkmark$ | R | L |  |  |
| A | E | P | L | E | I | I | L | H | L | P |  |  |
| A | E | A | F | E | A | I | P | R | A | 1 |  |  |
| S | E | M | E | V | Q | D | A | E | L |  |  |  |
| D | N | V | P | M | $F$ | I | S | 2 | N |  |  |  |
| K | E | S | c | E | S | 1 | S | C | L |  |  |  |
| Q | E | D | A | E | M | D | A | E | L |  |  |  |
| V | E | G | G | A | Q | $\checkmark$ | Q | $Q$ | v |  |  |  |
| $V$ | K | S | G | N | P | 1 | Q | P |  |  |  |  |
| A | E | N | P | D | I | F | A | v |  |  |  |  |
| P | V | P | A | W | A | R | A | L |  |  |  |  |
| S | P | S | G | w | S | N | V | E |  |  |  |  |
| S | T | c | G | S | H | F | M | L |  |  |  |  |
| 1. | V | A | L | S | $Y$ | S | S | P |  |  |  |  |
| F | E | D | E | 1. | H | P | D | 1 |  |  |  |  |
| H | A | G | L | D | A | F | 1 | v |  |  |  |  |
| 1 | E | k | S | 1. | 8 | K | S | L |  |  |  |  |
| N | V | v | D | S | S | 0 | K | P |  |  |  |  |
| R | E | G | E | D | K | E | L |  |  |  |  |  |
| $L$ | K | K | C | c | K | I | L |  |  |  |  |  |
| L | E | E | G | K | G | G | P |  |  |  |  |  |
| H | L | S | V | S | T | P | v |  |  |  |  |  |
| T | E | E | A | K | R | $Q$ | P |  |  |  |  |  |
| T | S | E | R | 1. | A | 1 | I |  |  |  |  |  |
| L | E | M | M | 1 | K | E | L |  |  |  |  |  |
| $\gamma$ | V | A | S | $v$ | L | G | L |  |  |  |  |  |

## Source

Leucine-rich repeats, immunoglobulin-like domains 3 Neuroligin 2
Cytoplasmic linker 2
Heat shock protein HSP 90-ß (HSP 90)
TatD DNase domain containing deoxyribonuclease 2
Immunoglobulin heavy chain variable region
IgE heavy chain
KIAA1076 protein
Unnamed protein product [Homo sapiens]
zine finger protein 136
SQEE253
Unnamed protein product (hum.)
ccctc-binding factor-like protein
Immunoglobulin alpha heavy chain variable region SFRSII protein
Neuroblastoma-amplified protein
NHP2 non-histone chromosome protein 2-1ike 1
CCT8 protein
Proliferation-associated protein 2G4
Similar to cadherin-related tumor suppressor precursor MYST histone acetyltransferase
KIAA1120 protein
Adaptor-related protein complex 2, $\alpha 2$ subunit variant
Chromosome 10 open reading frame 18
REC 11
Cholinergic receptor, $\alpha$ polypeptide 10
Glycerol 3-phosphate permease
Olfactory receptor, family 56 , subfamily $A$, member 3
Nucleoporin 133 kDa
Peptidylprolyl isomerase-like 1
HSPC320
Putative glycine-N-acyltransferase
ALL-1 protein
Titin isoform novex-3
Plasma membrane $\mathrm{Ca}(2+)$-ATPase isoform 2
Neuronal pentraxin 1
KIAA0929 protein
Similar to extensin-like protein
Nitrilase family, member 2
SnoN2
RAN-binding protein 2-11ke 1 isoform 2

## HLA-B*41:06

## Peptide position

$\begin{array}{llllllllllllll}1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 & 9 & 10 & 11 & 12 & 13 & 14\end{array}$

## Ligands

| K | E | K | E | T | P | T | P | G | E | D | 1 | Q |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A | E | $v$ | w | s | T | T | D | A | V | T | Q | v |
| 1 | K | L. | Y | K | K | K | T | G | K | D | v |  |
| D | K | L | L | V | N | Q | T | E | L | F | V |  |
| L | E | G | R | T | H | T | I | S | L | P |  |  |
| P | E | P | V | I | 1 | V | A | c | V | P |  |  |
| A | E | M | I | E | K | Y | F | V | S | P |  |  |
| A | E | R | V | G | A | G | A | P | V |  |  |  |
| $c$ | E | S | C | V | D | L | 1 | F | v |  |  |  |
| G | A | N | A | L | L | F | V | G | v |  |  |  |
| 1 | S | 1 | L | $L$ | $F$ | S | A | $P$ |  |  |  |  |
| R | E | R | R | D | N | $Y$ | V | P |  |  |  |  |
| $v$ | E | T | T | F | S | T | E | $P$ |  |  |  |  |
| G | E | P | R | $F$ | 1 | T | v |  |  |  |  |  |
| A | E | T | S | A | E | R | v |  |  |  |  |  |
| $Y$ | E | T | D | V | F | V | $v$ |  |  |  |  |  |
| 1 | E | A | L | 1 | $E$ | R | v |  |  |  |  |  |
| K | 1 | K | M | K | S | P | P |  |  |  |  |  |
| A | E | G | F | L | F | $V$ | v |  |  |  |  |  |
| N | E | P | K | $E$ | L | D | G |  |  |  |  |  |
| Q | G | P | $Y$ | G | M | D | v |  |  |  |  |  |
| H | E | V | L | M | L | L | P |  |  |  |  |  |

## Source

Hypothetical protein
Similar to GRIK2 protein
Glucose-regulated protein
Von Hippel-Lindau tumor suppressor-like
KIAA0564 protein isoform a
Phosphodiesterase H1
KIAA1356 protein
H2A histone family, member J isoform 2
Cyclin Gl interacting protein
Adenylate cyclase type I
Galanin receptor-like protein
Ribosomal Protein S17
Chondroitin sulfate proteoglycan 2
MHC class I antigen
Protocadherin 10 isoform 1 precursor
GTF2I repeat domain containing 2
KIAA0546 protein
NADH dehydrogenase subunit 5
ARNTL2 protein
Cadherin-7 precursor
Immunoglobulin heavy chain
Unnamed protein product (human)

Online Supplementary Table S2. List of promiscuous peptides.

| Peptide position |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1011 |
| K | E | G | K | P | P | I | S | v |  |
| G | E | V | D | P | K | v | A | L |  |
| T | E | D | I | P | V | K | T | L |  |
| $Y$ | E | E | I | F | V | K | N | M |  |
| A | E | A | L | E | R | M | F | L |  |
| Y | E | E | G | P | G | K | N | L | P |
| K | A | $Y$ | G | D | R | I | E | R | M |
| I | E | V | D | G | K | Q | V | E | L |
| A | E | E | K | A | A | V | T | S | L |
| G | E | K | F | E | D | E | N | F | I 1 |

Source
Unnamed protein (human)
Cell adhesion protein SQMI
Isoleucyl-tRNA synthetic, cytoplasmic
Tissue factor pathway inhibitor
Alpha globin
Cytochrome C oxidase VIIc
Heat shock protein gp96 precursor
Rho-related GTP-binding protein RhoB
caspr5 protein isoform 1
Peptidylprolyl cis-trans isomerase

Anchors for the corresponding $\mathrm{B}^{*} 41$ subtypes are printed in bold and auxiliary anchors are underlined.

## Presenting allele

## $\begin{array}{llllll}41: 01 & 41: 02 & 41: 03 & 41: 04 & 41: 05 & 41: 06\end{array}$

$+\quad+\quad$ - $\quad$ -
$-\quad+\quad+\quad-\quad-$
$-\quad+\quad+\quad-\quad$
$-\quad+\quad+\quad-\quad$

- $+\quad+\quad-\quad$ -
$+\quad+$
$+\quad-\quad+\quad-\quad-\quad-$
$-\quad+\quad+\quad+\quad-\quad-$
$-\quad+\quad-\quad+\quad-\quad-$
-     + 

Online Supplementary Table S3. Differentially selected peptides by B*41 subtypes.

| Peptide | Source | Length | Presenting allele |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | 41:01 | 41:02 | 41:03 | 41:04 | 41:05 | 41:06 |
| A E A ERMEL | Alpha globin (AA 25-34) | 9-mer | - | + | $+$ | - | - | - |
| $Y$ Y A EALERM | Alpha globin (AA 24-32) | 9-mer | - | - | - | + | - | - |
| $\begin{array}{r} G E K E D E N F I L \\ E E D E N E I L \end{array}$ | Peptidylprolyl cis-trans isomerase (AA 79-89) | 11-mer | - | + | + | + | - | - |
|  | Peptidylprolyl cis-trans isomerase (AA 82-89) | 8 -mer | - | - | - | + | - | - |
| SEMEVQ D A E L K A LSEMEVQ DAEL | Proliferation-assoc. protein 2G4 (AA 345-357) | 13-mer | - | - | - | + | - | - |
|  | Proliferation-assoc. protein 2G4 (AA 345-354) | $10-\mathrm{mer}$ | - | - | - | - | + | - |
| $\begin{aligned} & \text { AEVEGK } V \text { E L P E H A V L } \\ & \text { VE G K D L P E H } \end{aligned}$ | H. ribonuclear particle protein (AA 602-615) | $14 \text {-mer }$ | - | - | - | + | - | - |
|  | H. ribonuclear particle protein (AA 604-612) | 9-mer | - | - | + | - | - | - |
| $\begin{array}{rlllllll} V & E & E & E & R & G V K & L \\ & I & E & E & R & G & V & K \end{array}$ | Septin-2 (AA 86-95) | 10-mer | - | - | + | - | - | - |
|  | Septin-2 (AA 88-95) | 8 -mer | - | - | - | + | - | - |
| $\begin{array}{lllllllll} K & E & E & P & P & Q & P & Q & L \\ K & N & N & E & A & L & P & Q & Q \end{array}$ | Protein C20orf24 (AA 7-20) | 14-mer | - | - | - | + | - | - |
|  | Protein C20orf24 (AA 7-15) | 9 -mer | - | + | - | - | - | - |
| FEKTQEELTPFE | Apolipoprotein A-II | 12-mer | - | - | + | - | - | - |
| FEKTQEEL | Apolipoprotein A-II | 8 -mer | - | + | - | - | - | - |
| $\begin{array}{r} \text { DEVGGEALGRLL } \\ \text { GEALGRLL } \end{array}$ | Hemoglobin $\beta$ subunit (AA 21-32) | 12-mer | - | - | - | $+$ | - | - |
|  | Hemoglobin $\beta$ subunit (AA25-32) | 8-mer | - | - | - | $+$ | - | - |

Anchors for the corresponding $\mathrm{B}^{*} 41$ subtypes are printed in bold and auxiliary anchors are underlined.

Online Supplementary Table S4. Peptide contacts in the B*41:03/16-mer and B*41:04/11-mer structures.

| Peptide residue | \|HIA-B*41:03/AEMYMSVIEHPSPSPL |  | HIA-B* 41:04/HEEAVSVDRVL |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Interaction type | Contact ${ }^{\text {a }}$, | Peptide residue | Interaction | Contact |
| Ala | VDW ${ }^{\text {c }}$ | Y7, R62, E63, Y159, W167, Y171 | His, | VDW | M5, Y7, E63 Y159, W167, Y171 |
| Ala ${ }^{\mathrm{N}, 0}$ | $\mathrm{HB}^{\text {d }}$ |  | His ${ }^{\text {N,O}}$ | HB |  |
|  |  |  | Hisis ${ }^{\text {N }} 1$ | HB | $E 2^{\circ}$ |
| Glu2 | VDW | Y7, H9, T24, K45, R62, E63, I66, S67, Y99, Y159 | Glu | VDW | Y7, H9, T24, K45, E63, I66, S67, Y99, Y159 |
| $\mathrm{Clu}^{\mathrm{N}, 0}$ | HB |  | Gluz ${ }^{\mathrm{N}, 0}$ | HB |  |
| Glue ${ }^{0} \mathrm{l}^{0} 1, \mathrm{c}_{4}^{2}$ | $\mathrm{HB}, \mathrm{SB}^{\text {e }}$ |  | $\mathrm{Clu}_{2} \mathrm{O}_{\mathrm{E}, \mathrm{c}_{\mathrm{c}} 2}$ | $\mathrm{HB}, \mathrm{SB}^{\text {e }}$ |  |
|  | Wm' |  | $\mathrm{Clu}_{2} \mathrm{O}_{\mathrm{e},}, \mathrm{O}_{\mathrm{e}} 2$ | Wm |  |
| Met ${ }_{3}$ | VDW | I66, R97, Y99, Q155, D156, Y159 | Glus | VDW | I66, Y99, Q155, D156, Y159, V5 |
| Met ${ }^{\text {N, }}$, | HB, Wm |  | Clus ${ }^{\mathrm{v}, 0}$ | HB, Wm |  |
| Met ${ }^{\text {s\% }}$ | HB, Wm | R97 ${ }^{\text {N/ }{ }^{2}}$, D156 ${ }^{\text {osi }}$ | Glus ${ }^{\text {Ot, Oe2 }}$ | HB, SB, Wm | D156 ${ }^{00_{s} 1}, R g^{v_{n}, N_{n} \nu_{1}{ }^{2}}$ |
| Tyr ${ }_{\text {a }}$ | VDW | R62 |  |  |  |
|  |  |  | Vals | VDW | N70 ${ }^{\mathrm{V}^{2} 2}, E 3, R 9$ |
|  |  |  | Val5 ${ }^{\mathrm{N}, 0}$ | Wm | I $66^{\circ}$, $\mathrm{N} 70^{\text {or }}$ 1 |
|  |  |  | Ser ${ }_{6}$ | VDW | D8,R9 |
|  |  |  | Seror ${ }^{0}$ | HB | $R_{s}{ }^{N}$ |
|  |  |  | Ser ${ }^{\text {ory }}$ | HB, Wm | D80 ${ }^{\circ 8}$ |
|  |  |  | Val7 | VDW | T73, E76, R9, V10 |
|  |  |  | Val7 ${ }^{0}$ | HB | $V_{10}{ }^{N}$ |
| Proi3 | VDW | T73, P15 | Asps | VDW | A150, S6, V10 |
|  |  |  | Asp ${ }_{8}^{\text {or }} 1.100^{2}$ | HB |  |
| Ser ${ }_{4}$ | VDW | W147, V152 | Arg9 | VDW | W147, V152, Q155, V5, S6, V7 |
| Seri4 ${ }^{\text {a }}$ | Wm | Y116 ${ }^{\text {n }}$ | $\mathrm{Arg}^{\mathrm{N}, 0}$ | HB, Wm | Y116 ${ }^{\circ 0}$, S $^{0}$ |
|  |  |  | $\operatorname{Arg}^{\left(V_{1}, N_{n}{ }^{2}\right.}$ | HB, SB, Wm |  |
| Prols | VDW | T73, E76, S77, W147, P13 | Valı0 | VDW | T73, E76, S77, N80, W147, V7, D8 |
| Prols ${ }^{\circ}$ | HB | W147 ${ }^{\mathrm{N} \mathrm{e}^{1}}$ | Valio ${ }^{\text {N,0 }}$ | HB | W147 ${ }^{\mathrm{Ne}}, 177^{0}$ |
| Leul6 | VDW | S77, N80 Y84, L95, Y116, Y123, T143, K146, W147 | Leun | VDW | S77, N80, L81, Y84, L95, Y116, Y123, T143, W147 |
| Leuns ${ }^{\text {n, }, 0,0 x T}$ | HB, SB |  | Leun ${ }^{\mathrm{N}, 0,0 \mathrm{oxt}}$ | HB, SB |  |

${ }^{a}$ Atomic contacts determined using the CCP4i implementation of CONTACT ${ }^{1,2}$ and a cutoff of $4 \AA$. ${ }^{.}$Selected contacts between peptide residues are marked in italics. ${ }^{c}$ VDW - Van der Waals' interactions, defined as non-hydrogen bond contact distances of $4 \AA$ or less. ${ }^{4} H B$ - Hydrogen bond interactions, defined as contact distances of $3.5 \AA$ or less, between suitable atoms at appropriate angles, ${ }^{3}$ as determined in Coot. ${ }^{\text {e }} S B$ - Ionic interactions, defined as contact distances of $4.0 \AA$ or less between suitable residue atoms. 'Wm - Water mediated hydrogen bond (see " $d$ ").

Online Supplementary Table S5. Theoretically calculated ionization states for selected titratable groups in the B*41:03 and B*41:04 structures.

| Protein Model | Predicted Residue $\mathrm{pK}^{1 / 2} 2^{2}$ |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | His9 (6.6) | $\begin{aligned} & \text { Arg97 } \\ & \text { (12.0) } \end{aligned}$ | $\begin{gathered} \text { Asp114 } \\ (4.0) \end{gathered}$ | $\begin{gathered} \text { Asp156 } \\ \text { (4.0) } \end{gathered}$ | $\begin{gathered} p G \mid u 2 \\ (4.4) \end{gathered}$ | pClu3 (4.4) | $\begin{aligned} & \text { pArs99 } \\ & (12.0) \end{aligned}$ |
| B*41:03 | 1.8 | 21.0 | - | 1.2 | - | - | - |
| B* $41: 03 / 16 \mathrm{mer}^{\text {b }}$ | 4.1 | 26.3d | - | 0.82 | $-10.2^{\text {d }}$ | - | - |
| B*41:03 R97S ${ }^{\text {c }}$ | 5.2 | - | - | 2.3 | - | - | - |
| B*41:04 | 6.4 | - | 2.6 | 7.2 | - | - | - |
| B*41:04/11mer | 9.1 | - | 3.9 | 11.5 | -9.5 | 5.2 | 27.9 |
| B*41:04/11 mer $p$ R9A ${ }^{\text {c }}$ | 11.1 | - | 4.1 | 15.9 | -8.3 | 8.1 | - |







A


B


Online Supplementary Figure S2. Polymorphism alters the size and charge of the antigenbinding cleft in $B \star 41: 03$ and $B * 41: 04$ Surface representation of $(A)$ the $B * 41: 03 / 16 \mathrm{mer}$ and $(B)$ the $B * 41: 04 / 11$ mer structures, showing the antigen-binding cleft from above with peptide and solvent atoms removed. In each case the $\pm 6 \mathrm{kT} / \mathrm{e}$ electrostatic potential from the solvent accessible surface of the MHC has been rendered on the molecular surface. The N - and C-terminal ends of the cleft are marked by $\mathrm{Arg}_{62}$ and Lys ${ }_{146}$, respectively, while the D pocket aligns with GIn155. The polymorphism at positions 97 and 114 gives rise to an anti-gen-binding cleft in $B * 41: 04$ that is $140 \AA^{3}$ larger and more electronegative than $B * 41: 03$ in the region of pocket D . The molecular volume of each antigen-binding cleft (corresponding to the Connolly surface) was calculated using the CASTp server and a $1.4 \AA$ probe radius. ${ }^{5}$ Electrostatics calculations were carried out using only the heavy chain and $\beta-2-$ microglobulin coordinates of each structure. Briefly coordinate preparation (placing and optimizastion of hydrogen atoms assuming standard protonation at pH 7.0 , followed by assignment of atomic charge and radii parameters using the PARSE forcefield) was carried out using the PDB2PQR server (v1.5;). ${ }^{6}$ Electrostatic calculations were subsequently carried out using the APBS plugin in PyMOL (v1.1.0 ${ }^{7}$ and v1.2.x, ${ }^{8}$ respectively) with a 0.15 M concentration for the +1 and -1 ion species.

## References

1. Bailey $S$. The CCP4 suite: programs for protein crystallography. Acta Cryst. 1994;50(Pt 5):7603.
2. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydro-gen-bonded and geometrical features. Biopolymers. 1983;22(12):2577-637.
3. Baker EN, Hubbard RE. Hydrogen bonding in globular proteins. Prog Biophys Mol Biol. 1984;44(2):97-179.
4. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33(Web Server issue):W368-71.
5. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34 (Web Server issue):W116-8.
6. Dolinsky TJ, Nielsen JE, McCammon JA, Baker

NA. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32(Web Server issue):W665-7.
7. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001;98(18):10037-41.
8. DeLano WL. The PyMOL Molecular Graphics System, (http://www.pymol.org). 2002 [cited; Available from: http://www.pymol.org


[^0]:    Source
    Peptidylprolyl isomerase A
    Rho-related GTP-binding protein RhoB (H6)
    Hypothetical protein FLJJ0774
    caspr5 protein isoform 1
    Cytochrome C oxidase VIIC
    Protein C20orf24
    Unnamed protein product (hum.)
    plectin 1
    Kh type splicing regulatory protein; KSRP
    Wiskott-Aldrich syndrome gene-like protein
    A34653 cell adhesion protein SQM1
    Transgelin: SM22- $\alpha$
    Hypothetical protein SP329
    Hemoglobin $\alpha 1$ globin chain
    DNA polymerase subunit B
    Unnamed protein product [Homo sapiens]
    ARP1 actin-related protein 1 homolog A
    Mitochondrial DNA polymerase gamma
    THAP domain containing 6
    Transcription elongation factor A
    Apolipoprotein A-II

